Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

Unless you were sleeping under a rock, you are aware of the coordinated attacks on Iran’s nuclear facilities by Israel and the United States.

July 11, 2025

Vol.51 No.27

By Robert Peter Gale

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.

House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

Over 20 scientists whose grants have been canceled by the Trump administration presented posters on their now-terminated work at “The Things We’ll Never Know: A Science Fair of Canceled Grants.”

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the phase III EMBARK study evaluating Xtandi (enzalutamide), an androgen receptor signaling inhibitor, in combination with leuprolide, and as a monotherapy in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

July 11, 2025

Vol.51 No.27

Clinical

She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research

Don’t try to convince Col. Susan Fondy that lymphedema doesn’t merit interest from medical researchers.

As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures

We recently had the privilege of contributing to a CBS Sunday Morning story on the ongoing crisis in the federal support for research in general and cancer research in particular.

July 03, 2025

Vol.51 No.26

By George J. Weiner and Elizabeth M. Jaffee

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

YOU MAY BE INTERESTED IN

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research

As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures

Renew today!

Subscriber content

Never miss an issue!

Login

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

YOU MAY BE INTERESTED IN

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research

As cancer scientists, we must change how we engage with the public on the impact of NIH cutsWhat the scientific method obscures

Never miss an issue!

Login

As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures